Quadria to acquire minority stake in Aragen for USD 1.4 billion
Hyderabad: Aragen, a globally renowned Contract Research, Development and Manufacturing Organization (CRDMO), has announced that it has secured a USD 100 million investment from Quadria Capital, an Asia healthcare-focused Private Equity fund. The investment will result in Quadria acquiring a minority stake in Aragen, at an approximate valuation of USD 1.4 billion, primarily through a fresh capital infusion, with a small portion from the sale of shares by existing investors.
This funding will support Aragen’s strategic expansion of its capabilities and infrastructure, enabling the company to meet the growing demand for outsourcing services from innovators in the US and Europe.
With this investment, Quadria joins Goldman Sachs as the second strategic investor in Aragen. The announcement comes ahead of JPM Week 2025, where Aragen is expected to secure additional outsourcing partnerships.
“We are delighted to welcome Quadria to Aragen. This investment marks a pivotal moment as we scale to meet the needs of a rapidly evolving market,” said Manni Kantipudi, CEO, Aragen Life Science. “Our expanded capabilities will allow us to support the rising demand for integrated discovery and manufacturing services, and, most importantly, help our customers accelerate their programs to market faster and more efficiently.”
Dr. Amit Varma, Managing Partner and co-Founder of Quadria Capital, said, "The pharmaceutical outsourcing sector presents compelling growth opportunities, especially in the current environment which is driven by global supply chain reorganization. Aragen's impressive track record, customer-centric approach, and commitment to innovation make it an ideal partner for global pharmaceutical companies. We look forward to partnering with them and supporting their next phase of growth."
Aragen Life Sciences is a global R&D and manufacturing solutions provider to the global life sciences industries.
